| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
M. tuberculosis
BM-212 primarily targets MmpL3, a transmembrane protein that functions as a mycolic acid transporter in mycobacteria. MmpL3 is essential for the transport of mycolic acids, key components of the mycobacterial cell wall. By inhibiting MmpL3, BM-212 disrupts mycolic acid transport and cell wall integrity, leading to bacterial cell death. This mechanism is distinct from other antitubercular agents, making BM-212 effective against drug-resistant strains. |
|---|---|
| ln Vitro |
At 2 μg/mL and 8 μg/mL, BM212 completely destroys the hydrophobic nanodomains seen on S cells but has no discernible effect on R cells, causing significant structural changes in the M. abscessus CIP104536T S and R variants[3].
Mycobacterium avium's activity in U937 cells is inhibited by BM212 (0.5–10 μg/mL, 7 days) in a dose-dependent manner, with a MIC of 0.5 μg/mL and 100% inhibition beginning at a concentration of 1 μg/mL[4]. In vitro, BM-212 inhibits the growth of laboratory and clinical isolates of M. tuberculosis with MICs of 0.7-1.5 µg/ml, including strains resistant to ethambutol, isoniazid, rifampicin, and rifabutin. It also exerts bactericidal activity against intracellular bacilli residing in the U937 human histiocytic lymphoma cell line. At 2 µg/mL and 8 µg/mL, BM-212 completely destroys the hydrophobic nanodomains of M. abscessus S cells. It inhibits M. avium activity in U937 cells with a MIC of 0.5 µg/mL. |
| ln Vivo |
Specific in vivo activity data for BM-212 is not detailed in the provided search results. As a potent antimycobacterial agent with activity against drug-resistant strains, it is being investigated for its potential in treating tuberculosis and nontuberculous mycobacterial infections. Its ability to kill intracellular bacilli suggests it may be effective in vivo. Further studies are needed to characterize its in vivo efficacy, pharmacokinetics, and safety.
|
| Enzyme Assay |
The in vitro activity of BM-212 is assessed using standard antimicrobial susceptibility testing methods. The minimum inhibitory concentration (MIC) against M. tuberculosis and other mycobacteria is determined using the broth microdilution method. Serial two-fold dilutions of BM-212 are prepared in 7H9 broth. A standardized bacterial inoculum is added, and the plates are incubated at 37°C for 5-7 days. The MIC is determined as the lowest concentration that inhibits visible growth. For mechanistic studies, MmpL3 inhibition can be assessed by measuring mycolic acid transport.
|
| Cell Assay |
For cellular assays, the U937 human histiocytic lymphoma cell line is used to assess intracellular activity. Cells are infected with M. avium, and various concentrations of BM-212 (0.5-10 µg/mL) are added for 7 days. Intracellular bacterial growth is assessed by lysing cells and plating for colony counting. For mechanistic studies, the effect of BM-212 on cell wall integrity can be assessed by electron microscopy.
|
| Animal Protocol |
In vivo, BM-212 would be administered to animal models of tuberculosis or nontuberculous mycobacterial infection. The compound is formulated in a suitable vehicle and administered at various doses via oral or intraperitoneal routes. Efficacy is assessed by measuring bacterial burden in the lungs and spleen. Pharmacokinetic studies involve measuring BM-212 levels in plasma and tissues. In toxicological studies, the compound is administered at various doses, and toxicity endpoints are assessed.
|
| ADME/Pharmacokinetics |
BM-212 has a molecular weight of 414.37 g/mol and a molecular formula of C23H25Cl2N3. It has a density of 1.2±0.1 g/cm³, a boiling point of 528.3±50.0 °C, and a logP of 5.32. The compound is a solid powder and should be stored as a powder at -20°C for up to 3 years or in solvent at -80°C for up to 6 months. It is soluble in DMSO and other organic solvents.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for BM-212 is not available in the provided search results. As a potent antimycobacterial agent, its safety profile is still under investigation. The compound is intended for research purposes only and is not approved for human or veterinary use. Standard laboratory safety precautions should be followed when handling the compound. Comprehensive toxicological studies are required to establish its full safety profile.
|
| References |
|
| Additional Infomation |
BM-212 is a potent antimycobacterial agent and MmpL3 inhibitor. It is a founding lead compound of a well-characterized class of 1,5-diarylpyrrole antimycobacterial agents. BM-212 exhibits strong inhibitory activity against both M. tuberculosis and some nontuberculosis mycobacteria, including drug-resistant strains. Its unique mechanism of action makes it a promising candidate for the development of new antitubercular drugs. BM-212 is not approved for clinical use and is intended for research purposes only.
|
| Molecular Formula |
C23H25CL2N3
|
|---|---|
| Molecular Weight |
414.374
|
| Exact Mass |
413.142
|
| Elemental Analysis |
C, 66.67; H, 6.08; Cl, 17.11; N, 10.14
|
| CAS # |
146204-42-4
|
| Related CAS # |
146204-42-4;
|
| PubChem CID |
456926
|
| Appearance |
Solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
528.3±50.0 °C at 760 mmHg
|
| Flash Point |
273.3±30.1 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.622
|
| LogP |
5.32
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
480
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1CCN(CC2=C(C)N(C3=CC=C(Cl)C=C3)C(C4=CC=C(Cl)C=C4)=C2)CC1
|
| InChi Key |
YWZIODCWLMCMMW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H25Cl2N3/c1-17-19(16-27-13-11-26(2)12-14-27)15-23(18-3-5-20(24)6-4-18)28(17)22-9-7-21(25)8-10-22/h3-10,15H,11-14,16H2,1-2H3
|
| Chemical Name |
1-((1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine
|
| Synonyms |
BM-212; BM 212; BM212.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~5.56 mg/mL (~13.42 mM )
DMSO : ~1 mg/mL (~2.41 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.56 mg/mL (1.35 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.6 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.56 mg/mL (1.35 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.6 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.56 mg/mL (1.35 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% EtOH+40% PEG300+5% Tween-80+45% Saline: ≥ 0.56 mg/mL (1.35 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4133 mL | 12.0665 mL | 24.1330 mL | |
| 5 mM | 0.4827 mL | 2.4133 mL | 4.8266 mL | |
| 10 mM | 0.2413 mL | 1.2067 mL | 2.4133 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
